BridgeBio Pharma To Share Long-Term Efficacy, Safety Data In Participants With ATTR-CM From Its Phase 3 Trial Of Acoramidis At American College of Cardiology Annual Scientific Sessions & Expo - BridgeBio Pharma (NASDAQ:BBIO)
Published on March 23, 2026.
The American College of Cardiology (ACP) will share its long-term effectiveness and safety data with participants in its Phase 3 trial of Acoramidis. The company will also provide updates on the status of the drug. The ACCP will also share its data with the public.
Related Articles
Gas prices rising fast in Houston, could hit $4 a gallon as oil prices surge amid global conflict
Rising gas prices in Houston are causing disruption as a result of global conflict, with some stations seeing prices above $4 a gallon.
Dow futures rally nearly 1,000 points, oil tumbles below $100 after Trump orders 5-day pause on attacks on Iran power plants
US stock futures surged nearly 1,000 points after President Trump announced a five-day pause on nuclear attacks on Iran power plants, causing oil prices to drop.
Flutter Stock Climbs As Bill Targets Sports Contracts On Prediction Platforms - Flutter Entertainment (NYSE:FLUT)
Flutter Entertainment shares surged 10.29% as a bipartisan bill seeks to ban sports betting and casino-style games on prediction-market platforms.